Bank of Montreal Can boosted its stake in shares of Humana Inc (NYSE:HUM) by 20.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 498,875 shares of the insurance provider’s stock after acquiring an additional 85,446 shares during the quarter. Bank of Montreal Can owned 0.36% of Humana worth $168,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of HUM. Sun Life Financial INC raised its position in Humana by 120.7% during the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after purchasing an additional 204 shares during the last quarter. Financial Gravity Wealth Inc. bought a new position in Humana during the 1st quarter valued at approximately $113,000. Migdal Insurance & Financial Holdings Ltd. raised its position in Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 388 shares during the last quarter. Summit Trail Advisors LLC raised its position in Humana by 24,611.8% during the 1st quarter. Summit Trail Advisors LLC now owns 184,103 shares of the insurance provider’s stock valued at $184,000 after purchasing an additional 183,358 shares during the last quarter. Finally, NuWave Investment Management LLC bought a new position in Humana during the 2nd quarter valued at approximately $198,000. Institutional investors own 92.99% of the company’s stock.
In other news, SVP Cynthia H. Zipperle sold 4,886 shares of the stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $321.89, for a total value of $1,572,754.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the transaction, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Insiders sold a total of 40,284 shares of company stock valued at $13,147,715 in the last three months. Corporate insiders own 0.60% of the company’s stock.
Shares of NYSE:HUM opened at $318.35 on Friday. Humana Inc has a 52-week low of $231.90 and a 52-week high of $341.30. The company has a market capitalization of $46.64 billion, a PE ratio of 27.09, a PEG ratio of 1.69 and a beta of 0.97. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.17. Humana had a return on equity of 17.43% and a net margin of 2.48%. The firm had revenue of $14.26 billion during the quarter, compared to analyst estimates of $14.16 billion. During the same quarter in the prior year, the company earned $3.49 EPS. Equities research analysts forecast that Humana Inc will post 14.18 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Stockholders of record on Friday, September 28th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Thursday, September 27th. Humana’s dividend payout ratio is currently 17.08%.
A number of research analysts have commented on HUM shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $355.00 price target on shares of Humana in a research report on Thursday, August 2nd. Bank of America upped their price target on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Jefferies Financial Group upped their price target on Humana from $356.00 to $372.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Finally, Argus upped their price target on Humana to $375.00 and gave the company a “buy” rating in a research report on Tuesday, September 4th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus target price of $339.79.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.